|
CONNECT WITH US
|
|
||||||||||||||
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
In the current critical review we discuss these emerging trends in localized and systemic treatment as well as possible interesting combinations of the two modalities. Finally, we discuss the role of the new systemic agents in non–clear cell RCC.
This article will review the recent advances that form the current framework of therapy for RCC, as well as summarize key areas of progress and innovation in the evolving treatment paradigms for this disease.
Second Opinion series: The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass.
This article reviews the existing data to formulate an overall management strategy of metastatic RCC patients and discusses ongoing investigative efforts including sequencing, combination therapy and novel agents.
A 56-year-old man with renal cell carcinoma developed widely metastatic disease post nephrectomy, for which he was receiving cyclic sunitinib therapy (50 mg daily for 4 weeks, followed by a 2-week rest period). Toward the end of his second cycle of therapy, he developed minimally pruritic, bright red erythema and fine scale involving both sides of the scrotum.
A 71-year-old, previously healthy male, presents for evaluation of a new, solitary, painless, pedunculated bump on his chin. Past medical history is negative for surgery or transfusion, and he denies intravenous drug use. His review of systems is negative with the exception of complaints about mild right-sided postero-lateral flank pain.
A 15-year-old male, who carries the diagnosis of von Hipple-Lindau Syndrome, has been followed routinely with CT scans. A mass was subsequently found in the left kidney and the following image was viewed.
CancerNetwork speaks with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments, and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium.
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy